[시장보고서]RNA 요법 임상시험 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 모달리티별, 단계별, 치료 분야별, 지역별, 경쟁별, 예측(2020-2030년)

RNA 요법 임상시험 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 모달리티별, 단계별, 치료 분야별, 지역별, 경쟁별, 예측(2020-2030년)

RNA Therapy Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Modality, By Phase, By Therapeutic Areas, By Region and Competition, 2020-2030F

상품코드 : 1703280

리서치사 : TechSci Research

발행일 : 2025년 04월

페이지 정보 : 영문 184 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,497,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 7,940,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,550,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 RNA 요법 임상시험 시장 규모는 2024년에 28억 7,000만 달러, 2030년에는 40억 1,000만 달러에 달하며, 예측 기간 중 CAGR은 5.73%로 확대할 것으로 예측됩니다.

시장 개요
예측 기간	2026-2030
시장 규모 : 2024년	28억 7,000만 달러
시장 규모 : 2030년	40억 1,000만 달러
CAGR : 2025-2030년	5.73%
급성장 부문	희귀질환
최대 시장	북미

RNA 치료는 유전자 발현을 표적으로 삼아 다양한 질병을 치료할 수 있는 획기적인 접근법을 제공하는 의학 연구의 최첨단 분야입니다. 메신저 RNA(mRNA), small interfering RNA(siRNA), 안티센스 올리고뉴클레오티드(ASO) 등의 리보핵산(RNA) 분자를 활용하는 RNA 기반 치료는 유전자 활성을 조절하는 정밀 주도형 방법을 제공합니다. 이 접근법은 유전성 질환, 감염성 질환, 암, 그리고 현재 효과적인 치료법이 없는 희귀질환에 대한 대응에 큰 기대를 모으고 있습니다.

기존 의약품과 달리 RNA 치료는 유전자 수준에서 작용하므로 보다 정밀하고 맞춤화된 치료가 가능합니다. 전 세계에서 임상시험이 급증하는 것은 RNA 과학의 발전과 mRNA 백신과 같은 RNA 기반 제품 개발의 성공을 반영하여 헬스케어의 전망을 재정의하고 있습니다. 학계, 제약사, 연구기관이 협력하여 진행하는 이러한 임상시험은 규제 당국의 승인에 앞서 혁신적인 치료법의 안전성과 유효성을 평가하는 데 있으며, 매우 중요합니다.

시장 성장 촉진요인

RNA 기술 혁신의 가속

주요 시장이 해결해야 할 과제

전달 메커니즘의 복잡성

주요 시장 동향

맞춤형 의료와 정밀의료의 진전

시장 규모·예측
- 금액별
시장 점유율·예측
- 모달리티별(RNA 간섭, 안티센스 요법, 메신저 RNA, 올리고뉴클레오티드, 비안티센스, 비RNAi)
- 단계별(단계 I, 단계 II, 단계 III, 단계 IV)
- 치료 영역별(희귀질환, 항감염증, 항암, 신경계, 소화기·대사계, 근골격계, 순환기·호흡기, 감각 기관계, 기타)
- 지역별(북미, 유럽, 아시아태평양, 남미, 중동 및 아프리카)
- 기업별(2024)
제품 시장 맵
- 모달리티별
- 단계별
- 치료 영역별
- 지역별

제6장 북미의 RNA 요법 임상시험 시장 전망

시장 규모·예측
시장 점유율·예측
북미 : 국가별 분석
- 미국
- 캐나다
- 멕시코

제7장 유럽의 RNA 요법 임상시험 시장 전망

시장 규모·예측
시장 점유율·예측
유럽 : 국가별 분석
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인

제8장 아시아태평양의 RNA 요법 임상시험 시장 전망

시장 규모·예측
시장 점유율·예측
아시아태평양 : 국가별 분석
- 중국
- 일본
- 인도
- 한국
- 호주

제9장 남미의 RNA 요법 임상시험 시장 전망

시장 규모·예측
시장 점유율·예측
남미 : 국가별 분석
- 브라질
- 아르헨티나
- 콜롬비아

제10장 중동 및 아프리카의 RNA 요법 임상시험 시장 전망

시장 규모·예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
- 아랍에미리트
- 사우디아라비아
- 남아프리카공화국

제11장 시장 역학

촉진요인
과제

제12장 시장 동향과 발전

합병과 인수
제품 개발
최근 동향

제13장 경쟁 구도

IQVIA Inc.
ICON Plc
Laboratory Corporation of America Holdings
Charles River Laboratories International, Inc.
PAREXEL International Corp.
Syneos Health
Medpace Holdings, Inc.
Novotech Inc.
PPD Inc.
Veristat, LLC.

제14장 전략적 제안

제15장 조사회사 소개·면책사항

KSA

영문 목차

영문목차

Global RNA Therapy Clinical Trials Market was valued at USD 2.87 billion in 2024 and is projected to reach USD 4.01 billion by 2030, expanding at a CAGR of 5.73% during the forecast period.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 2.87 Billion
Market Size 2030	USD 4.01 Billion
CAGR 2025-2030	5.73%
Fastest Growing Segment	Rare Diseases
Largest Market	North America

RNA therapy represents a cutting-edge domain in medical research, offering a transformative approach to treating a wide range of diseases by targeting gene expression. Leveraging ribonucleic acid (RNA) molecules such as messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides (ASOs), RNA-based therapies provide a precision-driven method to regulate gene activity. This approach holds significant promise in addressing genetic disorders, infectious diseases, cancer, and rare conditions that currently lack effective treatment options.

Unlike conventional pharmaceuticals, RNA therapies operate at the genetic level, enabling more targeted and personalized treatment solutions. The surge in clinical trials globally reflects both advancements in RNA science and the successful development of RNA-based products, such as mRNA vaccines, which have redefined the healthcare landscape. These clinical trials, conducted through collaborations between academic institutions, pharmaceutical companies, and research organizations, are pivotal in evaluating the safety and efficacy of these innovative therapies prior to regulatory approval.

Key Market Drivers

Accelerated Innovation in RNA Technology

The market's growth is largely fueled by rapid technological advancements in RNA science, reshaping the future of medicine and therapeutic development. A critical area of progress is the refinement of RNA synthesis techniques, which now enable the creation of highly specific and efficient RNA molecules customized to target particular genes or disease pathways.

For instance, in May 2022, Moderna and the nonprofit research organization IAVI announced the initiation of Phase I clinical trials for an experimental mRNA-based HIV vaccine (mRNA-1644), with initial screenings in Rwanda and South Africa.

Further innovations in RNA modification have enhanced molecular stability, reducing degradation and improving biodistribution, which extends the therapeutic effect and reduces dosing frequency-key factors in improving patient compliance. Delivery technologies have also evolved significantly, with lipid nanoparticles and polymer-based carriers protecting RNA during systemic circulation and facilitating precise cellular uptake.

Additionally, combination RNA therapies-which integrate multiple RNA modalities or pair RNA treatments with other therapeutic strategies-are under exploration, offering synergistic potential for more comprehensive disease management.

Key Market Challenges

Complexities in Delivery Mechanisms

A major challenge within the RNA therapy clinical trials market is the effective delivery of RNA molecules to specific cells or tissues. Due to their inherent fragility, RNA molecules are susceptible to enzymatic degradation and immune system activation, limiting their therapeutic utility if not adequately protected and directed.

Moreover, RNA molecules typically exhibit short biological half-lives, requiring repeated administrations to maintain therapeutic levels. Efficient delivery systems are essential to ensure therapeutic RNA reaches the intended cellular targets while minimizing systemic exposure and off-target effects.

To overcome these barriers, researchers have developed advanced delivery platforms-most notably lipid nanoparticle formulations-that encapsulate RNA, shielding it from degradation and enhancing cellular uptake. These systems can be engineered for targeted delivery, ensuring better therapeutic outcomes and minimizing toxicity.

However, challenges remain, particularly in achieving consistent delivery across varied patient profiles and disease states, making delivery optimization a key area of ongoing research and development.

Key Market Trends

Advancing Personalized and Precision Medicine

The shift toward personalized and precision medicine is a transformative trend shaping the RNA therapy clinical trials landscape. This approach leverages individual genetic and molecular profiles to tailor therapeutic interventions, significantly improving treatment outcomes and minimizing adverse effects.

In RNA therapy, personalized medicine involves designing RNA-based therapies that target patient-specific mutations or gene expressions. This enables highly focused treatment strategies, especially for rare or complex conditions.

Precision medicine goes a step further by using genetic profiling and advanced diagnostics to predict how patients will respond to specific RNA therapies. This data-driven approach enhances treatment efficacy, optimizes resource allocation in clinical trials, and supports the development of more targeted RNA-based drug candidates.

Key Market Players

IQVIA Inc.

ICON Plc

Laboratory Corporation of America Holdings

Charles River Laboratories International, Inc.

PAREXEL International Corp.

Syneos Health

Medpace Holdings, Inc.

Novotech Inc.

PPD Inc.

Veristat, LLC.

Report Scope:

In this report, the Global RNA Therapy Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNA Therapy Clinical Trials Market, By Modality:

RNA interference

Antisense therapy Messenger RNA

Oligonucleotide

Non-antisense

Non-RNAi

RNA Therapy Clinical Trials Market, By Phase:

Phase I

Phase II

Phase III

Phase IV

RNA Therapy Clinical Trials Market, By Therapeutic Area:

Rare Diseases

Anti-infective

Anticancer

Neurological

Alimentary/Metabolic

Musculoskeletal

Cardiovascular Respiratory

Sensory

Others

RNA Therapy Clinical Trials Market, By Region:

North America

United States
Canada
Mexico

Europe

Germany
France
United Kingdom
Italy
Spain

Asia-Pacific

China
Japan
India
South Korea
Australia
Singapore

South America

Brazil
Argentina
Colombia

Middle East & Africa

UAE
Saudi Arabia
South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNA Therapy Clinical Trials Market.

Available Customizations:

Global RNA Therapy Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Types
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global RNA Therapy Clinical Trials Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Modality (RNA interference, Antisense therapy, Messenger RNA, Oligonucleotide, non-antisense, non-RNAi)
- 5.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
- 5.2.3. By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological, Alimentary/Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Others)
- 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
- 5.2.5. By Company (2024)
5.3. Product Market Map
- 5.3.1. By Modality
- 5.3.2. By Phase
- 5.3.3. By Therapeutic Areas
- 5.3.4. By Region

6. North America RNA Therapy Clinical Trials Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Modality
- 6.2.2. By Phase
- 6.2.3. By Therapeutic Areas
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States RNA Therapy Clinical Trials Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Modality
    - 6.3.1.2.2. By Phase
    - 6.3.1.2.3. By Therapeutic Areas
- 6.3.2. Canada RNA Therapy Clinical Trials Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Modality
    - 6.3.2.2.2. By Phase
    - 6.3.2.2.3. By Therapeutic Areas
- 6.3.3. Mexico RNA Therapy Clinical Trials Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Modality
    - 6.3.3.2.2. By Phase
    - 6.3.3.2.3. By Therapeutic Area

7. Europe RNA Therapy Clinical Trials Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Modality
- 7.2.2. By Phase
- 7.2.3. By Therapeutic Area
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany RNA Therapy Clinical Trials Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Modality
    - 7.3.1.2.2. By Phase
    - 7.3.1.2.3. By Therapeutic Area
- 7.3.2. France RNA Therapy Clinical Trials Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Modality
    - 7.3.2.2.2. By Phase
    - 7.3.2.2.3. By Therapeutic Area
- 7.3.3. United Kingdom RNA Therapy Clinical Trials Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Modality
    - 7.3.3.2.2. By Phase
    - 7.3.3.2.3. By Therapeutic Area
- 7.3.4. Italy RNA Therapy Clinical Trials Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Modality
    - 7.3.4.2.2. By Phase
    - 7.3.4.2.3. By Therapeutic Area
- 7.3.5. Spain RNA Therapy Clinical Trials Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Modality
    - 7.3.5.2.2. By Phase
    - 7.3.5.2.3. By Therapeutic Area

8. Asia-Pacific RNA Therapy Clinical Trials Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Modality
- 8.2.2. By Phase
- 8.2.3. By Therapeutic Area
- 8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China RNA Therapy Clinical Trials Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Modality
    - 8.3.1.2.2. By Phase
    - 8.3.1.2.3. By Therapeutic Area
- 8.3.2. Japan RNA Therapy Clinical Trials Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Modality
    - 8.3.2.2.2. By Phase
    - 8.3.2.2.3. By Therapeutic Area
- 8.3.3. India RNA Therapy Clinical Trials Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Modality
    - 8.3.3.2.2. By Phase
    - 8.3.3.2.3. By Therapeutic Area
- 8.3.4. South Korea RNA Therapy Clinical Trials Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Modality
    - 8.3.4.2.2. By Phase
    - 8.3.4.2.3. By Therapeutic Area
- 8.3.5. Australia RNA Therapy Clinical Trials Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Modality
    - 8.3.5.2.2. By Phase
    - 8.3.5.2.3. By Therapeutic Area

9. South America RNA Therapy Clinical Trials Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Modality
- 9.2.2. By Phase
- 9.2.3. By Therapeutic Area
- 9.2.4. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil RNA Therapy Clinical Trials Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Modality
    - 9.3.1.2.2. By Phase
    - 9.3.1.2.3. By Therapeutic Area
- 9.3.2. Argentina RNA Therapy Clinical Trials Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Modality
    - 9.3.2.2.2. By Phase
    - 9.3.2.2.3. By Therapeutic Area
- 9.3.3. Colombia RNA Therapy Clinical Trials Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Modality
    - 9.3.3.2.2. By Phase
    - 9.3.3.2.3. By Therapeutic Area

10. Middle East and Africa RNA Therapy Clinical Trials Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Modality
- 10.2.2. By Phase
- 10.2.3. By Therapeutic Area
- 10.2.4. By Country
10.3. MEA: Country Analysis
- 10.3.1. UAE RNA Therapy Clinical Trials Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Modality
    - 10.3.1.2.2. By Phase
    - 10.3.1.2.3. By Therapeutic Area
- 10.3.2. Saudi Arabia RNA Therapy Clinical Trials Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Modality
    - 10.3.2.2.2. By Phase
    - 10.3.2.2.3. By Therapeutic Area
- 10.3.3. South Africa RNA Therapy Clinical Trials Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Modality
    - 10.3.3.2.2. By Phase
    - 10.3.3.2.3. By Therapeutic Area

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition
12.2. Product Development
12.3. Recent Developments

13. Competitive Landscape

13.1. IQVIA Inc.
- 13.1.1. Business Overview
- 13.1.2. Company Snapshot
- 13.1.3. Products & Services
- 13.1.4. Financials (As Reported)
- 13.1.5. Recent Developments
- 13.1.6. Key Personnel Details
- 13.1.7. SWOT Analysis
13.2. ICON Plc
13.3. Laboratory Corporation of America Holdings
13.4. Charles River Laboratories International, Inc.
13.5. PAREXEL International Corp.
13.6. Syneos Health
13.7. Medpace Holdings, Inc.
13.8. Novotech Inc.
13.9. PPD Inc.
13.10. Veristat, LLC.